ATNX Athenex

Athenex Announces Participation in the 2020 RBC Capital Markets Global Healthcare Virtual Conference

Athenex Announces Participation in the 2020 RBC Capital Markets Global Healthcare Virtual Conference

BUFFALO, N.Y., May 19, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that management will participate in a fireside chat at the 2020 RBC Capital Markets Global Healthcare Virtual Conference on Wednesday, May 20, 2020, at 11:30 a.m. ET.

A live audio webcast of the presentation can be accessed through the Events & Presentations section of the Company's website at . An archived replay of the webcast will be available on the Company's website following the live presentation.

About Athenex, Inc.

Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development and commercialization of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. The Company’s current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation therapy. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments.  Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan; multiple locations in Chongqing, China; Manchester, UK; Guatemala City, Guatemala and Buenos Aires, Argentina. For more information, please visit .

CONTACTS

Investor Relations:

Tim McCarthy

Managing Director, LifeSci Advisors, LLC

Direct: 212-915-2564

Athenex, Inc.:

Randoll Sze

Chief Financial Officer

Email: 

Jacqueline Li

Corporate Development and Investor Relations

Email: 

EN
19/05/2020

Underlying

ATNXAthenex

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Athenex

 PRESS RELEASE
Free
ATNX ATHENEX

Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales...

Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process To Best Facilitate, Company Voluntarily Files Chapter 11 Proceedings Company Has Sufficient Resources to Support Athenex Pharma Solutions Operations and Fulfill APD Customer Orders During Process BUFFALO, N.Y., May 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX) (“Athenex” or the “Company”), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that, following an ongoi...

May 14, 2023 1 EN
 PRESS RELEASE
Free
ATNX ATHENEX

Athenex Provides Fourth Quarter and Full Year 2022 Financial Results a...

Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update Exploring a range of strategic alternatives Revenues from product sales from continued operations increased +27% Y/Y in 4Q 2022 and +33% for full year 2022 Net Loss attributable to Athenex was $34.2 million, or $4.28 per diluted share in 4Q2022, compared to $104.4 million, or $19.08 per diluted share, in the prior year quarter Cash, cash equivalents, and restricted cash balance of $35.6 million at year end Additional Phase 1 dose escalation study safety and preliminary efficacy data for KUR-...

March 20, 2023 1 EN
 PRESS RELEASE
Free
ATNX ATHENEX

Athenex Announces a Reverse Stock Split

Athenex Announces a Reverse Stock Split BUFFALO, N.Y., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it will effect a 1-for-20 reverse stock split of its issued common stock, effective at 12:01 a.m. Eastern Time on February 15, 2023. Beginning tomorrow, February 15, 2023, the Company's common stock will trade on a split-adjusted basis. At the Company's Special Meeting of Stockholder...

February 14, 2023 1 EN
 PRESS RELEASE
Free
ATNX ATHENEX

Athenex Announces MHRA Decision on Oral Paclitaxel

Athenex Announces MHRA Decision on Oral Paclitaxel MHRA denies Oral Paclitaxel for metastatic breast cancer based solely on chemistry, manufacturing and control (CMC) issuesAthenex plans to request a review of the MHRA decision by an independent panel The MHRA application was supplemented with safety data from the iSPY 2 study and no major clinical efficacy or safety concerns were expressed BUFFALO, N.Y., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for...

January 3, 2023 1 EN
 PRESS RELEASE
Free
ATNX ATHENEX

Athenex Announces Quantum Leap Healthcare Collaborative Reports Positi...

Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer Oral Paclitaxel combination regimen has graduated in this Phase 2 trial in the triple negative breast cancer subgroup BUFFALO, N.Y., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions announced that collaborators at the...

December 20, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch